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Background: Gastric cancers have poor overall survival despite recent advancements in early detection methods,
endoscopic resection techniques, and chemotherapy treatments. Vaccinia viral therapy has had promising therapeutic
potential for various cancers and has a great safety profile. We investigated the therapeutic efficacy of a novel
genetically-engineered vaccinia virus carrying the human sodium iodide symporter (hNIS) gene, GLV-1 h153, on
gastric cancers and its potential utility for imaging with 99mTc pertechnetate scintigraphy and 124I positron emission
tomography (PET).
Methods: GLV-1 h153 was tested against five human gastric cancer cell lines using cytotoxicity and standard viral
plaque assays. In vivo, subcutaneous flank tumors were generated in nude mice with human gastric cancer cells,
MKN-74. Tumors were subsequently injected with either GLV-1 h153 or PBS and followed for tumor growth. 99mTc
pertechnetate scintigraphy and 124I microPET imaging were performed.
Results: GFP expression, a surrogate for viral infectivity, confirmed viral infection by 24 hours. At a multiplicity of
infection (MOI) of 1, GLV-1 h153 achieved > 90% cytotoxicity in MNK-74, OCUM-2MD3, and AGS over 9 days, and >70%
cytotoxicity in MNK- 45 and TMK-1. In vivo, GLV-1 h153 was effective in treating xenografts (p < 0.001) after 2 weeks of
treatment. GLV-1 h153-infected tumors were readily imaged by 99mTc pertechnetate scintigraphy and 124I microPET
imaging 2 days after treatment.
Conclusions: GLV-1 h153 is an effective oncolytic virus expressing the hNIS protein that can efficiently regress
gastric tumors and allow deep-tissue imaging. These data encourages its continued investigation in clinical settings.
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Gastric cancer is one of the most prevalent malignant tu-
mors, especially in Asia [1]. Although early detection
methods, development of endoscopic or surgical resection,
and more effective chemotherapies have improved the
overall survival in patients with gastric cancer, the progno-
sis of patients with advanced gastric cancer is still poor* Correspondence: fongy@mskcc.org
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stated.[2-4]. Most conventional chemotherapy treatments have
demonstrated moderate efficiency. One possible explan-
ation for the resistance of gastric cancer to conventional
therapy might be its non-susceptibility to apoptosis [5].
However, oncolytic viruses have great therapeutic effects
against cancer cells which express high levels of ribonucle-
otide reductase, DNA-repair enzymes, and are thus resist-
ant to apoptosis [6,7]. Many of these characteristics which
make gastric cancer cells resistant to chemotherapy, make
them susceptible to oncolytic viral therapy. Thus, gene. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tive for the treatment of gastric cancer [8].
Oncolytic viral therapy has been studied over the past
century and shown success in preclinical and clinical
testing as a novel cancer treatment modality [9]. Vac-
cinia virus (VACV) strains are particularly attractive as
potential antitumor agents, as they can incorporate large
amounts of foreign DNA without reducing their replica-
tion efficiency. Moreover, VACV has shown a great
safety profile in humans [10-12]. Lastly, in addition to its
therapeutic potential, VACV has also been used as a
noninvasive imaging technique allowing clinicians to
track therapeutic gene delivery in the body [10,13].
In this publication, we examined the therapeutic potential
of a novel VACV expressing the human sodium iodide sym-
porter (hNIS), GLV-1 h153, against gastric cancers in vitro
and in vivo, and tested its potential as an imaging tool.
Materials and methods
Cell lines
Human gastric cancer AGS cells (a gastric adenocarcinoma
epithelial cell line) were obtained from American Type
Culture Collection (ATCC; Manassas, VA) and were cul-
tured in Ham’s F-12 K Medium. Human OCUM-2MD3
cells were a gift from Dr. Masakazu Yashiro (Osaka City
University Medical School, Japan) and were grown in Dul-
becco’s Modified Eagle’s Medium (DMEM). MKN-74 and
TMK-1 cells were provided by Dr. T. Suzuki (Fukushima
Medical College, Japan) and were cultured in Roswell Park
Memorial Institute (RPMI). MKN-45 was obtained as a gift
from Dr. Yutaka Yonemura (Kanazawa University, Japan)
and was maintained in RPMI. African green monkey kid-
ney fibroblast (Cercopithecus aethiops; CV-1) cells used for
viral plaque assays were purchased from ATCC (Manassas,
VA) and grown in the Minimum Essential Medium
(MEM). All media were supplemented with 10% FBS,
1% penicillin, and 1% streptomycin.
Virus
GLV-1 h153 is a replication-competent, recombinant vac-
cinia virus derived from its parental strain, GLV-1 h68, via
homologous recombination. It contains four inserted cas-
settes encoding Renilla Aequorea luciferase- green fluores-
cent protein (RUC-GFP) fusion protein, a reversely inserted
human transferrin receptor (rTfr), β-galactosidase, and hu-
man sodium iodide symporter (hNIS) into the F14.5,
J2R (encoding thymidine kinase), and A56R (encoding
hemagglutinin) loci of the viral genome.GLV-1 h153
was provided by Genelux Corporation (R&D facility in
San Diego, CA, USA).
Cytotoxicity assay
4 × 104 cells per well of each cell line were plated in 12-
well plates and incubated in a 5% CO2 humidifiedincubator at 37°C overnight. GLV-1 h153 was added to
each well at varying Multiplicity of Infection (MOIs) of
0.01, 0.1, and 1.0. Viral cytotoxicity was tested using a
lactate dehydrogenase (LDH) assay daily. Cells were
washed with PBS once, and then lysed with 1.35% Triton
X-100 (Sigma, St. Louis, MO). The intracellular LDH re-
lease following lysis was subsequently measured with
CytoTox 96® (Promega, Madison, WI) on a spectropho-
tometer (EL321e, Bio- Tek Instruments) at 490 nm. Re-
sults are expressed as the percentage of surviving cells,
which were calculated as the LDH release of infected
samples compared to uninfected control. All conditions
were tested in triplicate.Viral replication assay
Supernatants from each infected well were collected
daily and immediately frozen at −80°C. Serial dilutions
of all supernatant samples were made to perform stand-
ard viral plaque assays on confluent CV-1 cells. All sam-
ples were measured in triplicates.In vivo murine flank tumor therapy
All animal experiments were performed under approved
protocols and in accordance with ethical guidelines of the
Institutional Animal Care and Use Committee (IACUC)
at Memorial Sloan-Kettering Cancer Center (MSKCC).
MKN-74 xenografts were established in 6- to 8-week-old
female nude mice (NCI:Hsd:Athymic Nude-nu, Harlan)
by subcutaneously injecting 5 × 106 MKN-74 cells into the
right flank. Tumor growth was recorded twice a week
using a digital caliber and tumor volume was calculated
using the equation, a × b2 × 0.5, in which a and b are the
largest and smallest diameters, respectively. When tumors
reached a diameter of approximately 6–8 mm in 10 days,
animals were grouped into control and treatment groups
with equitable tumor sizes. A single dose of 2 × 106
plaque-forming units (PFUs) of GLV-1 h153 in 100 μL
PBS or 100 μL of PBS as control were injected intratumo-
rally to each designated tumor. Animals were observed
daily for any signs of toxicity, and sacrificed when their tu-
mors reached a diameter of approximately 15 mm.Fluorescent imaging (Maestro)
In vivo GFP images were obtained using the CRi Maestro
system (Cambridge Research and Instrumentation, Wo-
burn, MA) using the appropriate filters (excitation = 445–
490 nm, emission = 515 nm long-pass filter, acquisition
settings = 500–720 in 10 nm). After each image was ob-
tained, it was spectrally unmixed to remove the back-
ground fluorescence. Images were quantified using region
of interest (ROI) analysis software that is supplied with
the Maestro system.
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SPECT imaging
Five MKN-74 xenografts were intratumorally injected
with 2 × 107 PFUs GLV-1 h153 and 5 with PBS as con-
trols. Two days after infection, 200 μCi of 99mTc per-
technetate was administered via tail vein injection. 99mTc
pertechnetate images were obtained over 10 min, 3 hours
after radiotracer administration. Imaging was performed
using the dual-detector gamma camera sub-system of the
X-SPECT small-animal SPECT-CT system (Gamma Medica,
Northridge, CA). The X-SPECT γ-camera system was cali-
brated by imaging a mouse-size (30 mL) cylinder filled with
a measured concentration (MBq/mL) of 99mTc using a
photopeak energy window of 126 to 154 keV and low-
energy high-resolution collimation. The resulting 99mTc im-
ages were exported to Interfile and then imported into the
ASIPro (Siemens Pre-clinical Solutions, Knoxville, TN)
image processing software environment. By ROI analysis, a
system calibration factor (in cpm/pixel per MBq/mL) was
derived. Animal images were likewise exported to Interfile
and then imported into ASIPro and parameterized in terms
of the decay-corrected percentage injected dose per
gram (%ID/g) based on the foregoing calibration factor,
the administered activity, the time after administration
of imaging, and the image duration.
In vivo PET imaging
Three MKN-74 xenografts were injected intratumorally
with 2 × 107 PFU GLV-1 h153 and two with PBS. Two
days after viral injection, 300 μCi of 124I was adminis-
tered via tail vein injection. One hour after radiotracer
administration, 3-dimensional list-mode data were ac-
quired using an energy window of 350 to 700 keV, and a
coincidence timing window of 6 nanoseconds. Imaging
was performed using a Focus 120 microPET dedicated
small animal PET scanner (Concorde Microsystems Inc,
Knoxville, TN). These data were sorted into 2-dimensional
histograms by Fourier rebinning. The count rates in the re-
constructed images were converted to activity concentra-
tion (%ID/g) using a system calibration factor (MBq/mL
per cps/voxel) derived from imaging of a mouse size phan-
tom filled with a uniform aqueous solution of 18F. Image
analysis was performed using ASIPro.
Statistical analysis
Significant differences between groups were determined
using Student’s t test (Excel 2007; Microsoft, Redmond,
WA, USA). A p-value < 0.05 was considered significant.
Results
Cytotoxicity assay
All five human gastric cancer cell lines were susceptible
to oncolysis by GLV-1 h153 (Figure 1). The MKN-74,
OCUM-2MD3, and AGS cell lines were more sensitiveto viral lysis compared to MKN-45 and TMK-1 cells. All
cell lines demonstrated a dose-dependent response, with
greater and faster cell kill at higher MOIs. In MKN-74,
OCUM-2MD3, and AGS cell lines, more than 90% of
the cells were killed by day 9 at an MOI of 1. The
MKN-74 cell line was particularly susceptible to viral
oncolysis, with greater than 77% cell kill by day 9 at the
lowest MOI of 0.01.
Viral replication
Standard viral plaque assays demonstrated efficient viral
replication of GLV-1 h153 in all gastric cancer cell lines
at an MOI of 1 (Figure 2). MKN-74 demonstrated the
highest viral titer with a peak titer of 1.06 × 106 PFUs
per well, a 26-fold increase from initial dose, by day 7.
In vivo murine xenografts therapy with GLV-1 h153
To establish the cytolytic effects of GLV-1 h153 in vivo,
mice bearing MKN-74 xenografts were treated with a
single dose of intratumoral injection of GLV-1 h153 or
PBS. Treated tumors demonstrated sustained/continu-
ous tumor regression over a four-week period. By day
28, the mean tumor volume of the treatment group was
221.6 mm3 (Figure 3). One animal demonstrated a
complete tumor regression. In contrast, all of the control
tumors continued to grow with a mean volume of
1073.2 mm3 by day 28 (t-test, comparing treatment and
control group on day 28, p < 0.001). There was no sig-
nificant change in body weight in either group, and no
morbidity or mortality related to GLV-1 h153 treatment
was observed.
In vitro and in vivo GFP expression
GFP expression was monitored by fluorescence micros-
copy 1, 3, 5, 7, and 9 days after viral infection at an MOI
of 1.0. Most MKN-74 cells were infected and expressed
GFP by day 7 (Figure 4A). In vivo, GFP signal can be de-
tected only at the xenograft injected with GLV-1 h153
(Figure 4B).
Functioning hNIS expression imaged by 99mTc-
pertechnetate scintigraphy and 124I PET
All MKN-74 xenografts injected with GLV-1 h153
showed localized accumulation of 99mTc radioactivity in
the flank tumors while no radioactivity cumulation in
control tumors (Figure 5A). GLV-1 h153-infected MKN-
74 tumors also facilitated 124I radioiodine uptake and
allowed for imaging via PET (Figure 5B), while PBS-
injected tumors could not be visualized.
Discussion
Gastric cancer is the fourth most common malignancy
and the second most frequent cause of cancer-related
death world-wide [1,14]. Recurrence or distant metastasis
Figure 1 Cytotoxicity of GLV-1 h153 against 5 human gastric cancer cell lines in vitro. All cell lines sustained significant cytotoxicity at an MOI of 1,
three cell lines were sensitive at an MOI of 0.1, and two cell lines demonstrated an exquisite sensitivity to GLV-1 h153 even at the lowest MOI of 0.01.
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cause of death [15]. While chemotherapy is a useful adju-
vant therapy compared to surgical therapy alone, its thera-
peutic potential is limited [16]. Most gastric cancers are
resistant to currently available chemotherapy regimens.
Therefore, novel therapeutic agents are needed to improveFigure 2 In vitro quantification of viral replication by GLV-1 h153
in human gastric cancer cell lines. Virus was collected from the
wells of cells infected at an MOI of 1. Viral plaque assays demonstrated
efficient viral replication in all 5 cell lines, reaching the highest viral
proliferation (1.06 × 106 viral plaque-forming units by day 7) in the cell
line, MKN-74, which represents a 26-fold increase from its initial dose.
Figure 3 GLV-1 h153 suppresses MKN-74 tumor growth. 2 × 106
viral particles of GLV-1 h153 or PBS were injected intratumorally into
nude mice bearing subcutaneous flank tumors of MKN-74. Inhibition
of tumor growth due to treatment with GLV-1 h153 started by day
15 (p < 0.001). Tumor volumes shown represent mean volumes from
5 mice in each treatment groups.
Figure 4 Green fluorescent protein (GFP) expression of MKN-74 in vitro and in vivo. A. MKN-74 cells were infected with GLV-1 h153 and
showed strong green fluorescence by day 7, demonstrating effective infection (magnification 100×). B. MKN-74 flank tumors were treated with
2 × 106 viral particles of GLV-1 h153. Green fluorescence of tumor with the Maestro scanner indicates successful infection and tumor-specific
localization of GLV-1 h153.
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sponsive to conventional therapies. Oncolytic viral
therapy is a promising approach to cancer treatment
that depends on the ability of viruses to infect, repli-
cate within, and lyse a host cell [17,18]. In this study,Figure 5 Nuclear imaging of GLV-1 h153-infected MKN-74 xenografts
infection and 3 hours after radiotracer administration. Tumors treated with GL
seen due to native expression of NIS, and the bladder is seen from excretion
48 hour after GLV-1 h153 injection shows enhanced signal in GLV-1 h153-infewe described the cytotoxic effects of GLV-1 h153, a
novel recombinant VACV carrying the hNIS gene, on
gastric cancer cells in vitro. We further demonstrated
that GLV-1 h153-infected gastric cancer xenografts
expressed functioning hNIS protein that allowed for. A. 99mTc pertechnetate scanning was performed 48 hours after
V-1 h153 virus are clearly visualized (arrow). The stomach and thyroid are
of the radiotracer. B. Axial, coronal, and sagittal views of an 124I PET image
cted MKN-74 tumors (arrow).
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tumor regression in vivo.
A variety of viruses have shown oncolytic properties
including adenovirus, herpes simplex virus, Newcastle
disease virus, vesicular stomatitis virus, and reovirus
[17]. Among a variety of oncolytic viral agents, vaccinia
virus has several advantages. VACV exclusively replicates
in the cytoplasm without using the host’s DNA-synthesis
machinery, thereby lowering the risk of integration of
the viral genome into the host genome [10]. A large
amount of foreign DNA (up to 25 kb) can be incorpo-
rated without significantly reducing the viral replication
efficiency [19]. Moreover, vaccinia has been proven to
have a good safety profile as it has been historically
given to millions during the smallpox vaccination. It also
demonstrates efficient replication and a broad range of
host cell tropisms [10]. Several preclinical studies have
shown that systemic injection of recombinant VACV
into xenografts resulted in high viral titers in tumors
only, indicating tumor-specific colonization [11,20,21].
There is a small concern that patients who have received
smallpox vaccination in the past have neutralizing anti-
body against the virus. This could potentially result in
compromised treatment efficacy. However, in the blood,
complement plays a more important role in inactivating
VACV than neutralizing antibodies. We therefore pre-
dict that the presence of neutralizing antibodies in pa-
tients should not hinder VACV treatment; however, a
higher treatment dose might be required.
Genetically engineered VACVs have shown efficacy
in the treatment of a wide range of human cancers
[12]. GLV-1 h168 has already shown to be an effective
diagnostic and therapeutic vector in several human
tumor models, including breast tumor, mesothelioma,
pancreatic cancers, and squamous cell carcinoma [11]
The hNIS protein, which is an intrinsic membrane
glycoprotein with 13 putative transmembrane domains,
actively transports both Na+ and I- ions across the cell
membrane [22]. Functioning hNIS protein can uptake
several commercially available radio-nucleotides, in-
cluding 123I, 124I, 125I, 131I, 99mTc and 188Re [22,23]. In
this study, GLV-1 h153-mediated expression of hNIS
protein in infected MKN-74 xenografts resulted in a
localized 99mTc and 124I radiotracer uptake. Our results
suggest that hNIS gene expression via viral vector can
be used as a non-invasive imaging modality to monitor
tumor progression and treatment effects.
A single intratumoral injection of GLV-1 h153 in
MKN-74 xenografts exhibited localized intratumoral
GFP and hNIS expression. Moreover, there was no evi-
dence of viral spread to any other organs based on
GFP imaging, 99mTc scintigraphy, and 124I PET, indi-
cating tumor-specific viral infection and activity. We
also demonstrated that GLV-1 h153 is effective andsafe in treating gastric tumors in a murine xenograft
model. The GLV-1 h153-treated group was continu-
ously followed until day 35 and there was no tumor re-
growth (data not shown between day 28 and 35). The
control group had to be sacrificed in accordance to our
approved animal protocol on day 28. Expressing the
hNIS gene in an otherwise non-hNIS-expressing tissue
is exciting. It could potentially make use of the well-
established radioiodine imaging and therapy in other
non-thyroid originated cancers. Several studies have
shown promising results in a variety of tumors using
radioiodine treatment via tumor-specific expression of
the hNIS gene, including medullary thyroid carcinoma
[24], prostate cancer [25], colon cancer [26], and breast
cancer [27]. Tumor-specific hNIS expression using
GLV-1 h153 can maximize localized radioiodine accu-
mulation and minimize non-specific uptake in other
organs. Based on our promising results, it would be of
significant clinical importance to evaluate the effect of
combination therapy of GLV-1 h153 and radioiodine.Conclusion
This study demonstrates a novel oncolytic VACV engi-
neered to express the hNIS can effectively infect, repli-
cate within, and cause regression of gastric cancer in a
murine xenograft model. GFP expression can serve as a
surrogate of viral infectivity. In vivo, GLV-1 h153 in-
fected cells can be readily imaged with 99mTc scintig-
raphy and 124I PET imaging. These data provide further
support for future investigation of GLV-1 h153 as a
treatment agent and a non-invasive imaging tool in the
clinical settings.
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